{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:13:14Z","timestamp":1794467594442,"version":"4.9.1"},"reference-count":72,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>Parkinson's disease (PD) is a growing public health problem and biologically targeted therapeutics (BTTs) that slow disease progression are urgently needed. However, the development of effective BTTs is challenging as PD is a clinically defined syndrome with pathobiological heterogeneity and the pathobiological process begins many years before the onset of clinically detectable motor symptoms. Testing BTTs in a biomarker-defined population at an earlier stage in the disease course, before a clinical PD diagnosis, may be the key to achieving this objective. The recent emergence of biological definitions of neuronal \u03b1-synuclein disease (NSD) and research frameworks for staging disease represent the first step towards testing BTTs in biomarker-defined prodromal populations. While biomarker-defined populations are essential for implementing precision therapeutic approaches, selecting and prioritizing BTTs for testing in early-stage populations is also critical, and requires consideration of biological relevance, safety, and operational feasibility. Here, in preparation for such studies, we review the landscape of publicly available PD BTTs organized by mechanistic pathways and targets, and summarize scientific, safety, and operational considerations relevant to early-stage, biomarker-defined trials targeting NSD participants prior to PD clinical diagnosis. Recognizing that there are shared biological mechanisms across neurodegenerative disorders, we complement this review of the PD therapeutic target landscape with a review of publicly available Alzheimer's dementia and amyotrophic lateral sclerosis BTTs and provide a comprehensive list of agents for reference.<\/jats:p>","DOI":"10.1177\/1877718x261493297","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:33:18Z","timestamp":1791462798000},"page":"1377-1388","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Considerations for therapeutic targets for clinical trials in biomarker-characterized prodromal Parkinson's disease populations"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-4041","authenticated-orcid":false,"given":"RB","family":"Schneider","sequence":"first","affiliation":[{"name":"University of Rochester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7209-1441","authenticated-orcid":false,"given":"G","family":"Skibinski","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson's Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8797-2042","authenticated-orcid":false,"given":"B","family":"Fiske","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson's Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-7550","authenticated-orcid":false,"given":"CM","family":"Kopil","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson's Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-9403","authenticated-orcid":false,"given":"K","family":"Merchant","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-1644","authenticated-orcid":false,"given":"T","family":"Simuni","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21995"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/114.5.2283"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13687"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00405-2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29329"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30449-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105567"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210279"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2026.108266"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.78250"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-230363"},{"key":"e_1_3_3_15_2","unstructured":"Hope List Therapies in development current version.xlsx. Google Docs https:\/\/drive.google.com\/file\/d\/1NeSyFA37b9IbUzryRRP-EqrgScjCRL-3\/view?usp=sharing&usp=embed_facebook (accessed 15 August 2025)."},{"key":"e_1_3_3_16_2","unstructured":"Fiske B Klapper K Schorken Z et al. Parkinson\u2019s priority therapeutic clinical pipeline report. Zenodo 2025. Epub ahead of print 5 June 2025. DOI: 10.5281\/zenodo.15604012."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30190"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115177"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102183"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05292"},{"key":"e_1_3_3_22_2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025","volume":"11","author":"Cummings JL","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement N Y N 2025; 11: e70098.","journal-title":"Alzheimers Dement N Y N"},{"key":"e_1_3_3_23_2","unstructured":"Suneja Y Delma C Hickman E et al. Cracking the ALS code: can cutting-edge science and optimized clinical strategies break through historial challenges?"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12770-x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107257"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf304"},{"key":"e_1_3_3_27_2","unstructured":"AC Immune SA. An Adaptive Phase 2 double-blind randomized placebo-controlled multicenter study to evaluate the safety tolerability immunogenicity and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease. Clinical Trial Registration NCT06015841 clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06015841 (18 November 2025 accessed 15 January 2026)."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03101-8"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110595"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134316"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4193"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-019-02025-9"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00684-6"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28075"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4066"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00822-2"},{"key":"e_1_3_3_37_2","unstructured":"Cedarbaum J. An exploratory study of the potential for rational immune system manipulation to prevent emergence of synucleinopathy manifestations in persons with REM sleep behavior disorder (RBD). Clinical Trial Registration NCT06996652 clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06996652 (3 August 2026 accessed 6 August 2026)."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126277"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010818-021358"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2026.1880374"},{"key":"e_1_3_3_41_2","unstructured":"Longevity Biotech Australia Pty Ltd (subsidiary). A two-part single and multiple ascending dose trial of the safety tolerability pharmacokinetics and pharmacodynamics of LBT-3627 in healthy participants and in participants with Parkinson\u2019s disease. Clinical Trial Registration NCT06466525 clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06466525 (8 May 2025 accessed 6 August 2026)."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00421"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01057-z"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.81a.12121"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/frdem.2024.1458038"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28858"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy143"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4725"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-026-01275-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-026-01084-4"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02730-0"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111777"},{"key":"e_1_3_3_53_2","article-title":"From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics","volume":"22","author":"Roy A","year":"2025","unstructured":"Roy A, Dawson VL, Dawson TM. From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics. Neurother J Am Soc Exp Neurother 2025; 22: e00712.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00459-9"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02808-3"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1308577"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00173"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39970-9"},{"key":"e_1_3_3_59_2","unstructured":"Biopharma H. HanAll Biopharma Daewoong pharmaceutical and NurrOn pharmaceuticals announce successful completion of a first-in-human study for potential disease-modifying therapy for Parkinson\u2019s disease https:\/\/www.prnewswire.com\/news-releases\/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-announce-successful-completion-of-a-first-in-human-study-for-potential-disease-modifying-therapy-for-parkinsons-disease-302315158.html (accessed 28 October 2025)."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00544-w"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106314"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.25322"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4650"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.795036"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107053"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.009"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00676-7"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25462"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00323-0"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-026-00551-7"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.05.2115"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100328"},{"key":"e_1_3_3_73_2","unstructured":"Combination therapies funding call. Cure Parkinson\u2019s https:\/\/cureparkinsons.org.uk\/research\/for-researchers\/apply-for-funding\/combination-therapies-funding-call\/ (accessed 18 March 2026)."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261493297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261493297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261493297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:47:11Z","timestamp":1793947631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261493297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":72,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/1877718X261493297"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261493297","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}